Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOUCH: Neoadjuvant Palbociclib + Hormonal Therapy + HER2 Blockade vs Paclitaxel + HER2 Blockade in HR+/HER2+ Early Breast Cancer
NCT03644186Phase 2Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Apr 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of palbociclib in breast cancer, sponsored by ETOP IBCSG Partners Foundation. Started Apr 2019; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03644186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03644186.